<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30184029</article-id><article-id pub-id-type="pmc">6122766</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Is Preoperative Clopidogrel Resistance a Predictor of Bleeding and
Risks in Patients Undergoing Emergency CABG Surgery?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kizilay</surname><given-names>Mehmet</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Aslan</surname><given-names>Zeynep</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Vural</surname><given-names>Unsal</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Balci</surname><given-names>Ahmet Yavuz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Aglar</surname><given-names>Ahmet Arif</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Yilmaz</surname><given-names>Sahin</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiovascular Surgery, Dr. Siyami Ersek Training and
Research Hospital, University of Health Sciences, &#x00130;stanbul, Turkey.</aff><aff id="aff2">
<label>2</label> Department of Cardiovascular Surgery, Derince Training and Research
Hospital, University of Health Sciences, Derince, Kocaeli, Turkey.</aff><aff id="aff3">
<label>3</label>
<label>3</label> Department of Anesthesiology, Dr. Siyami Ersek Training and
Research Hospital, University of Health Sciences, &#x00130;stanbul, Turkey.</aff><author-notes><corresp id="c1">Correspondence Address: Mehmet Kizilay, Department of
Cardiovascular Surgery Dr. Siyami Ersek Training and Research Hospital,
University of Health Sciences, Tibbiye Cad Selimiye, Uskudar, &#x00130;stanbul,
Turkey, Zip code: 34668. E-mail: <email>kzlay@yahoo.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jul-Aug</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jul-Aug</season><year>2018</year></pub-date><volume>33</volume><issue>4</issue><fpage>330</fpage><lpage>338</lpage><history><date date-type="received"><day>11</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aims of this study were to determine whether the detection of
preoperative clopidogrel resistance in patients undergoing cardiac surgery
while using clopidogrel could play a guiding role in the prediction of
postoperative excessive bleeding, transfusion requirements, and risks and to
provide clinically significant data.</p></sec><sec><title>Methods</title><p>Two hundred and twenty-two patients [median age: 59.4 (38-83) years;
38 females] undergoing emergency and elective coronary artery bypass
graft (CABG) surgeries in our clinic were evaluated prospectively. Patients
with multiple systemic diseases, other than diabetes mellitus (DM) and
hypertension (HT), were excluded. Patients receiving clopidogrel were also
evaluated for clopidogrel resistance and grouped according to the results of
this test. Assessments of platelet functions were performed by multiplate
impedance aggregometry method and adenosine diphosphate test.</p></sec><sec><title>Results</title><p>The use of postoperative fresh blood replacement and platelet transfusion was
higher in patients receiving clopidogrel than in those not receiving it
(<italic>P</italic>=0.001, <italic>P</italic>=0.018). DM, HT, myocardial
infarction, and the number of presentation to the emergency room were
significantly higher in patients receiving clopidogrel than in those not
receiving it (<italic>P</italic>&#x0003c;0.05). No significant difference was
determined between patients with and without clopidogrel resistance
regarding the amount of bleeding during and after surgery, erythrocyte
suspension and fresh-frozen plasma transfusion rates, preoperative troponin
values, ejection fraction values, and length of hospital stays
(<italic>P</italic>&#x0003e;0.05).</p></sec><sec><title>Conclusion</title><p>We think that resistance studies in patients receiving clopidogrel before
cardiac surgery are not efficient to predict bleeding and bleeding-related
complications in patients undergoing emergency and elective CABG
surgeries.</p></sec></abstract><kwd-group><kwd>Platelet Aggregation Inhibitors</kwd><kwd>Thienopyridines</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Acute Coronary Syndrome</kwd></kwd-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute coronary
syndrome</td><td rowspan="12" align="left" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ERT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Electrophoresis release
test</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ADP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Adenosine
diphosphate</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FFP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Fresh-frozen plasma</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ASA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acetylsalicylic
acid</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Hb</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hemoglobin</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AUC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Area under the
aggregation curve</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hypertension</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BARC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Bleeding Academic
Research Consortium</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
graft</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">INR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= International Normalized
Ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IQR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interquartile range</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CURE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Clopidogrel in Unstable
angina to prevent Recurrent</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LIMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left internal mammary
artery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ischemic Events</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Myocardial
infarction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DAPT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Dual anti-platelet
therapy</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Diabetes mellitus</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RIMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Right internal mammary
artery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ejection fraction</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">STEMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= ST-elevation myocardial
infarction</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Clopidogrel is a thienopyridine derivative adenosine diphosphate (ADP) receptor
blocker which inhibits platelet aggregation specifically and
irreversibly<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. The effect of clopidogrel begins within 2 hours after
oral administration and lasts for 5-7 days. The time required to both the platelet
inhibition response and the antiplatelet activity return to normal levels varies.
Due to its antiplatelet effect, clopidogrel is used to prevent ischemic events in
patients with acute coronary syndrome (ACS) and before percutaneous coronary
intervention (PCI)<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Approximately 10-15% of ACS patients undergo coronary
artery bypass graft (CABG) surgery since they are not suitable for PCI. In addition,
patients with unfavorable coronary anatomy for PCI and those who underwent failed
PCI become candidates for emergency CABG surgery<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In most of these patients, one thing is
certain: the antiplatelet agent, particularly clopidogrel, used before PCI and hence
is considered to be responsible for postoperative bleedings and it has been a
controversial subject for a long time<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. In current guidelines, it is recommended to cease
clopidogrel 5-7 days before surgery in patients who will undergo elective CABG
surgery<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>. The clinical benefits of
using dual anti-platelet therapy (DAPT) with acetylsalicylic acid (ASA) and P2Y12
inhibitors in patients with ACS or after PCI have been well established. Premature
discontinuation of antiplatelets before CABG surgery increases the risk of a
thromboembolic event, while the continuation of antiplatelets increases the risk of
bleeding. However, in such conditions, it is not clarified exactly which
antiplatelet agent, as a drug companion to ASA, should be used or when it should be
discontinued<sup>[<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Although it is reported in some articles that emergency conditions do not cause
additional CABG complications, there are some articles that point to an increase in
postoperative complications of CABG surgery such as bleeding, cardiac tamponade,
reoperation, and excessive blood transfusion under emergency
conditions<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Unfortunately, there is no algorithm to evaluate the
benefits and risks on this subject and which aims to solve this problem.</p><p>Another issue related to clopidogrel is the resistance. The rate of clopidogrel
resistance vary between 4% and 30% in current literature<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Because of this resistance,
efficient antiplatelet treatment cannot be provided to some patients despite the use
of clopidogrel and this may cause complications such as stent and graft thrombosis
and myocardial infarction (MI). On the other hand, the possibility of a considerable
amount of resistant cases suggests the question: "Is the predetermination of
resistance to clopidogrel in patients who will undergo CABG surgery while receiving
clopidogrel a guide for conditions such as possible postoperative bleeding and
related complications?". Considering this condition, in our study, we investigated
complications of clopidogrel such as the amount of bleeding during and after CABG
surgery, use of blood and blood products, tamponade, and reoperation. Also, because
of the prevalence of clopidogrel resistance, we decided to perform this study to
investigate the effect of the identification of patients with and without
clopidogrel resistance on the use of blood and blood products and postoperative
complications.</p></sec><sec sec-type="methods"><title>METHODS</title><p>Two hundred and twenty-two patients [median age: 59.4 (38-83) years; 38
females] undergoing emergency and elective CABG surgeries in our clinic,
between January 2015 and July 2016, were evaluated prospectively. Patients were
included in the study after receiving medical and ethical approvals. They were
divided into two groups: patients undergoing emergent or urgent surgery while
receiving clopidogrel preoperatively [n=111; median age: 58 years (38-83); 13
females] and patients undergoing elective surgery without clopidogrel use
preoperatively [n=111; median age: 61.8 years (42-85); 28 females].
The patients receiving clopidogrel were also grouped inter se as those with
clopidogrel resistance and those without it. The onset date of follow-up of patients
for ACS in the emergency room was the inclusion date in the study; hospital
discharge date after surgery was the exclusion date from the study. Patients with
heart valve surgery, ventricle restoration, aortic surgeries, patients undergoing
reoperation with bleeding disorder, thrombocytopenic patients, patients with renal
failure, dialysis-dependent patients and patients with multiple systemic diseases
[except hypertension (HT) and diabetes mellitus [(DM)] were
excluded from the study.</p><p>In this study, patients were compared in terms of age, gender, DM, HT, ejection
fraction (EF), time of surgery (emergent or elective), hemoglobin (Hb), platelet,
International Normalized Ratio (INR), and troponin values in the preoperative
period. They were also compared regarding cardiopulmonary bypass (CPB) and
cross-clamping times in intraoperative period and bleeding, tamponade and
reoperation rates, use of homologous blood and blood products, drain removal, length
of intensive care unit (ICU) stay, and hospitalization in postoperative period.
Transfusion decision was made after a thorough examination of the patient's clinical
status and based on amount of bleeding, Hb (cut-off value: 8-9 mg/dL) level, and
hematocrit (cut-off value: 24-27%) level.</p><sec><title>Surgical Intervention</title><p>Median sternotomy and standard CPB techniques were used in all the patients. CPB
was established with aortocaval cannulation; myocardial protection was ensured
with 30-32&#x002da;C systemic hypothermia and intermittent antegrade cold blood
cardioplegia administered at 20-minute intervals. After cross-clamping and
primarily distal anastomoses were performed; following removal of
cross-clamping, secondarily proximal anastomoses were performed under partial
cross-clamping.</p><p>The patients' postoperative bleedings were evaluated. Bleedings occurring within
the first postoperative 48 hours were evaluated as postoperative bleedings.
Bleeding Academic Research Consortium (BARC) criteria were considered for
CABG-related bleeding<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Development of cardiac tamponade and volume of
chest tube drainage &#x0003e;600 mL within the first hour or &#x02265;200 mL/h for 3
hours were criteria for reoperation. Patients' drains with &#x02264;100 mL serous
drainage for 4 hours were removed during subsequent drain follow-ups. The
patients were followed-up in the ward after an average follow-up of 1 day in
ICU. Patients in good condition were discharged on postoperative day 5-7.</p><p>Multiplate(r) (2013 Roche Diagnostics International Ltd. CH-6343 Rotkreus
Switzerland) impedance aggregometry method was used for platelet reactivity
studies in patients receiving clopidogrel<italic>.</italic> The test was
performed by taking a fasting blood sample on the first postoperative morning.
Blood samples were taken into blood collection tubes containing hirudin as the
anticoagulant agent. ADP test (2012 Roche Diagnostics GmbH Sandhofer Strasse
116D68305 Mannheim) was performed. Aggregation procedure was performed within 2
hours after taking a sample. The area under the aggregation curve (AUC/minute)
was calculated with multiplate aggregometry measurements. Values of 0-200
AUC/min, 200-425 AUC/min, and 425-998 AUC/min were considered to indicate 80%
sensitivity to the drug, dose that should be arranged, and resistance to the
drug, respectively.</p></sec><sec><title>Statistical Analyses</title><p>Continuous variables were expressed as mean (&#x000b1;) standard deviation and
categorical variables were expressed as number and percentage (%). For
intergroup comparisons of continuous variables, Shapiro-Wilk test was used
regarding the conformity of the data to a normal distribution. Mann-Whitney U
test was used for comparisons of data without normal distribution between
groups. Categorical or nominal variables were analyzed by using Yate's corrected
chi-square test and Fisher's exact chi-square test. The effect of preoperative
demographic characteristics on postoperative complications was investigated by
using Yate's corrected chi-square test and Fisher's exact chi-square test.
Spearman's correlation test was used for comparison of the correlations between
groups. Data observed to have a relationship were investigated by logistic
regression analysis. Values of <italic>P</italic>&#x02264;0.05 were significant.
SPSS statistical program (SPSS for Windows, version 20.0, SPSS Inc, New York,
USA) was used for statistical analysis.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The patients were divided into two groups as patients receiving and not receiving
clopidogrel preoperatively. Additionally, the patients receiving clopidogrel were
also divided into two groups as those with clopidogrel resistance and those without
it. Distribution of the cases according to demographic features was shown in <xref rid="t1" ref-type="table">Table 1</xref>. DM, HT, MI, and the number of
presentation to the emergency room were significantly higher in patients receiving
clopidogrel than in those not receiving it (<xref rid="t1" ref-type="table">Table
1</xref>; <italic>P</italic>&#x0003c;0.05). Similarly, a significant difference was
determined between troponin (<italic>P</italic>=0.029) and Hb levels
(<italic>P</italic>=0.03). However, no significant difference was determined
between preoperative EF values (<italic>P</italic>=0.088) and platelet and INR
levels (<italic>P</italic>=0.175, <italic>P</italic>=0.128).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Statistical analysis of preoperative demographic characteristics of the
cases.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/><col width="14%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="3">&#x000a0;</th><th align="center" colspan="4" rowspan="1">Use of clopidogrel</th><th align="center" rowspan="3" colspan="1"><italic>P</italic></th></tr><tr><th align="center" colspan="2" rowspan="1">Absent</th><th align="center" colspan="2" rowspan="1">Present</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="2" colspan="1">0.032<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">53</td></tr><tr><td align="left" rowspan="2" colspan="1">DM</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="2" colspan="1">0.019<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="2" colspan="1">HT</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="2" colspan="1">&#x0003c;0.001<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">38</td></tr><tr><td align="left" rowspan="2" colspan="1">MI</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="2" colspan="1">&#x0003c;0.001<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">71</td></tr><tr><td align="left" rowspan="2" colspan="1">Angiography</td><td align="left" rowspan="1" colspan="1">Emergency</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="2" colspan="1">0.001<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Elective</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="2" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1">Emergency</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">78</td><td align="center" rowspan="2" colspan="1">0.001<sup><xref ref-type="table-fn" rid="TFN2">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Elective</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">45</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td><td align="center" rowspan="1" colspan="1"><bold>IQR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td><td align="center" rowspan="1" colspan="1"><bold>IQR</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">Age (year), mean&#x000b1;sd</td><td align="center" rowspan="1" colspan="1">60.41</td><td align="center" rowspan="1" colspan="1">9.42</td><td align="center" rowspan="1" colspan="1">58.34</td><td align="center" rowspan="1" colspan="1">9.28</td><td align="center" rowspan="1" colspan="1">0.100<sup><xref ref-type="table-fn" rid="TFN3">c</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative EF (%)</td><td align="center" rowspan="1" colspan="1">55</td><td align="center" rowspan="1" colspan="1">45, 60</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">45, 60</td><td align="center" rowspan="1" colspan="1">0.088<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Troponin (ug/L) (n= 135)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">0.01, 0.85</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.04, 1.25</td><td align="center" rowspan="1" colspan="1">0.029<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative Hb (g/L)</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">12, 14.2</td><td align="center" rowspan="1" colspan="1">13.8</td><td align="center" rowspan="1" colspan="1">12.5, 14.9</td><td align="center" rowspan="1" colspan="1">0.030<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative Plt (thousand/&#x000b5;L)</td><td align="center" rowspan="1" colspan="1">238</td><td align="center" rowspan="1" colspan="1">200, 289</td><td align="center" rowspan="1" colspan="1">217</td><td align="center" rowspan="1" colspan="1">184, 283</td><td align="center" rowspan="1" colspan="1">0.175<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative INR</td><td align="center" rowspan="1" colspan="1">1.02</td><td align="center" rowspan="1" colspan="1">0.96, 1.1</td><td align="center" rowspan="1" colspan="1">1.04</td><td align="center" rowspan="1" colspan="1">1, 1.08</td><td align="center" rowspan="1" colspan="1">0.128<sup><xref ref-type="table-fn" rid="TFN1">a</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>a</label><p>Mann-Whitney U test;</p></fn><fn id="TFN2"><label>b</label><p>Pearson's chi-square test;</p></fn><fn id="TFN3"><label>c</label><p>independent samples t-test.</p></fn><fn id="TFN4"><p>DM=diabetes mellitus; EF=ejection fraction; Hb=hemoglobin;
HT=hypertension; INR=International Normalized Ratio; IQR=interquartile
range, reported as first quartile, third quartile; Mean &#x000b1; sd
=Mean &#x000b1; standard deviation; MI=myocardial infarction;
Plt=platelet <italic>P</italic> values. A <italic>P</italic> value of
&#x0003c;0.05 was considered significant.</p></fn></table-wrap-foot></table-wrap><p>When postoperative findings were evaluated (<xref rid="t2" ref-type="table">Table
2</xref>), no difference was determined between groups regarding the use of
protamine sulfate, but the use of tranexamic acid (10 mg/kg) was higher in patients
receiving clopidogrel than in those not receiving it, although it was not
significant. No statistically significant difference was determined between the
numbers of reoperations (<italic>P</italic>=0.553). The volumes of postoperative
fresh blood and platelet replacement were significantly higher in patients receiving
clopidogrel than in those not receiving it (<italic>P</italic>=0.001,
<italic>P</italic>=0.017). Between the groups receiving and not receiving
clopidogrel, no statistically significant difference was observed in postoperative
EF levels, drain removal periods, types of graft used in CABG surgery [left
internal mammary artery (LIMA) or right internal mammary artery (RIMA)],
length of ICU stay, and hospitalization periods (<italic>P</italic>&#x0003e;0.05; <xref rid="t2" ref-type="table">Table 2</xref>). Use of clopidogrel showed correlation
at a rate of 26% with whole blood replacement (<italic>P</italic>=0.01,
r<sup>2</sup>=0.26). Use of tranexamic acid showed correlation at a rate of 12%
with use of clopidogrel (<italic>P</italic>=0.076, r<sup>2</sup>=0.12). Namely,
while the use of clopidogrel was moderately correlated with blood replacement, it
was weakly correlated with use of tranexamic acid.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Analysis of postoperative clinical data according to use of clopidogrel.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="3">&#x000a0;</th><th align="center" colspan="4" rowspan="1">Clopidogrel</th><th align="center" rowspan="3" colspan="1"><italic>P</italic></th></tr><tr><th align="center" colspan="2" rowspan="1">Absent</th><th align="center" colspan="2" rowspan="1">Present</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Protamine sulfate</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">96</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="2" colspan="1">0.404<sup><xref ref-type="table-fn" rid="TFN6">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="2" colspan="1">Tranexamic acid</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">92</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="2" colspan="1">0.075<sup><xref ref-type="table-fn" rid="TFN6">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">61</td></tr><tr><td align="left" rowspan="2" colspan="1">Reoperation</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="2" colspan="1">0.553<sup><xref ref-type="table-fn" rid="TFN6">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="2" colspan="1">Pericardial effusion (n= 71)</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="2" colspan="1">0.566<sup><xref ref-type="table-fn" rid="TFN6">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">74</td></tr><tr><td align="left" rowspan="2" colspan="1">Tamponade (n= 71)</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="2" colspan="1">0.587<sup><xref ref-type="table-fn" rid="TFN7">d</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="2" colspan="1">LIMA/RIMA (n= 211)</td><td align="left" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">49.5</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">50.5</td><td align="center" rowspan="2" colspan="1">0.683<sup><xref ref-type="table-fn" rid="TFN7">d</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">RIMA</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">Saphenous graft</td><td align="left" rowspan="1" colspan="1">Used</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">92,8</td><td align="center" rowspan="1" colspan="1">110</td><td align="center" rowspan="1" colspan="1">99.1</td><td align="center" rowspan="1" colspan="1">0.035<sup><xref ref-type="table-fn" rid="TFN5">a</xref>,<xref ref-type="table-fn" rid="TFN7">d</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Not used</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">7,1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.9</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Use of platelet transfusion (unit)</td><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1,8</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">9.0</td><td align="center" rowspan="1" colspan="1">0.018<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" rowspan="1" colspan="1">98,2</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">91.0</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Fresh blood replacement (unit)</td><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">14,4</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">36.9</td><td align="center" rowspan="1" colspan="1">0.001<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">95</td><td align="center" rowspan="1" colspan="1">85,6</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">63.1</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td><td align="center" rowspan="1" colspan="1"><bold>IQR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td><td align="center" rowspan="1" colspan="1"><bold>IQR</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">Bleeding (mL)</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">200, 500</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">200, 500</td><td align="center" rowspan="1" colspan="1">0.987<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">CPB time (minute)</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">77, 116</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">74, 110</td><td align="center" rowspan="1" colspan="1">0.248<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Cross-clamping time</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">45. 78</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">42, 66</td><td align="center" rowspan="1" colspan="1">0.106<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Number of bypasses</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2, 3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">2, 4</td><td align="center" rowspan="1" colspan="1">0.207<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Postoperative bleeding (24h)</td><td align="center" rowspan="1" colspan="1">750</td><td align="center" rowspan="1" colspan="1">600, 1000</td><td align="center" rowspan="1" colspan="1">750</td><td align="center" rowspan="1" colspan="1">500, 1100</td><td align="center" rowspan="1" colspan="1">0.680<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Amount of postoperative drainage</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">700, 1350</td><td align="center" rowspan="1" colspan="1">1000</td><td align="center" rowspan="1" colspan="1">700, 1450</td><td align="center" rowspan="1" colspan="1">0.778<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Erythrocyte (unit)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0, 1</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0, 1</td><td align="center" rowspan="1" colspan="1">0.533<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">FFP (unit)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0, 2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0, 2</td><td align="center" rowspan="1" colspan="1">0.100<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Postoperative platelet number</td><td align="center" rowspan="1" colspan="1">170</td><td align="center" rowspan="1" colspan="1">147, 208</td><td align="center" rowspan="1" colspan="1">179</td><td align="center" rowspan="1" colspan="1">143, 227</td><td align="center" rowspan="1" colspan="1">0.216<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Postoperative EF (%) (n= 71)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">45, 55</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">45, 60</td><td align="center" rowspan="1" colspan="1">0.160<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Drain removal (day)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2, 3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2, 3</td><td align="center" rowspan="1" colspan="1">0.621<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Intensive care (day)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1, 2</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1, 1</td><td align="center" rowspan="1" colspan="1">0.706<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Clinical stay (day)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5, 6</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">5, 6</td><td align="center" rowspan="1" colspan="1">0.429<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Hospitalization (day)</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">6, 7</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">6, 8</td><td align="center" rowspan="1" colspan="1">0.477<sup><xref ref-type="table-fn" rid="TFN5">a</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>a</label><p>Mann-Whitney U test;</p></fn><fn id="TFN6"><label>b</label><p>Pearson's chi-square test;</p></fn><fn id="TFN7"><label>d</label><p>Fisher's exact test.</p></fn><fn id="TFN8"><p>CPB=cardiopulmonary bypass; EF=ejection fraction; FFP=fresh-frozen
plasma; IQR=interquartile range, reported as first quartile, third
quartile; LIMA=left internal mammary artery; RIMA=right internal mammary
artery</p></fn></table-wrap-foot></table-wrap><p>During comparison of patients with and without clopidogrel resistance, among the ones
receiving clopidogrel, no significant difference was determined between troponin
values, preoperative and postoperative EF values, total bleeding volumes during and
after surgery, amount of erythrocyte suspension [electrophoresis release test
(ERT)] and fresh-frozen plasma (FFP) transfusions, and length of
hospitalization (<xref rid="t3" ref-type="table">Table 3</xref>;
<italic>P</italic>&#x0003e;0.05). However, lengths of ICU stay and cross-clamping times
of patients without clopidogrel resistance were statistically significant (<xref rid="t3" ref-type="table">Table 3</xref>; <italic>P</italic>=0.020;
<italic>P</italic>=0,040). No correlation was observed between clopidogrel
resistance and CPB times (<xref rid="t3" ref-type="table">Table 3</xref>;
<italic>P</italic>&#x0003e;0.05). Presence of clopidogrel resistance did not affect
the numbers of effusions and tamponades developing during the follow-up period
(<xref rid="t3" ref-type="table">Table 3</xref>;
<italic>P</italic>&#x0003e;0.05).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>The effect of presence or absence of clopidogrel resistance in the patients
on postoperative events and clinical medications.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/><col width="10%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="3">&#x000a0;</th><th align="center" colspan="4" rowspan="1">Clopidogrel resistance</th><th align="center" rowspan="3" colspan="1"><italic>P</italic></th></tr><tr><th align="center" colspan="2" rowspan="1">Absent</th><th align="center" colspan="2" rowspan="1">Present</th></tr><tr><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th><th align="center" rowspan="1" colspan="1">n</th><th align="center" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">Effusion</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="2" colspan="1">0.566<sup><xref ref-type="table-fn" rid="TFN10">b</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">26.1</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">73.9</td></tr><tr><td align="left" rowspan="2" colspan="1">Tamponade</td><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">22.7</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">77.3</td><td align="center" rowspan="2" colspan="1">0.587<sup><xref ref-type="table-fn" rid="TFN11">d</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">60</td></tr><tr><td align="left" rowspan="2" colspan="1">LIMA/RIMA</td><td align="left" rowspan="1" colspan="1">LIMA</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">22.1</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">77.9</td><td align="center" rowspan="2" colspan="1"><sup><xref ref-type="table-fn" rid="TFN12">&#x02021;</xref></sup>-</td></tr><tr><td align="left" rowspan="1" colspan="1">RIMA</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="2" colspan="1">Saphenous graft</td><td align="left" rowspan="1" colspan="1">Used</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="2" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Not used</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="2" colspan="1">Use of platelet transfusion (unit)</td><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="2" colspan="1">0.321</td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">94.4</td></tr><tr><td align="left" rowspan="2" colspan="1">Fresh blood replacement (unit)</td><td align="left" rowspan="1" colspan="1">Present</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">42.6</td><td align="center" rowspan="2" colspan="1">0.005<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Absent</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">94.1</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">57.4</td></tr><tr><td align="left" colspan="2" rowspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td><td align="center" rowspan="1" colspan="1"><bold>IQR</bold></td><td align="center" rowspan="1" colspan="1"><bold>Median</bold></td><td align="center" rowspan="1" colspan="1"><bold>IQR</bold></td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" colspan="2" rowspan="1">Troponin (ug/L)</td><td align="center" rowspan="1" colspan="1">0.36</td><td align="center" rowspan="1" colspan="1">0.01, 0.55</td><td align="center" rowspan="1" colspan="1">0.33</td><td align="center" rowspan="1" colspan="1">0.06, 1.7</td><td align="center" rowspan="1" colspan="1">0.390<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Preoperative EF (%)</td><td align="center" rowspan="1" colspan="1">52.5</td><td align="center" rowspan="1" colspan="1">47.5, 60</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">45, 60</td><td align="center" rowspan="1" colspan="1">0.999<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Postoperative EF (%)</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">45, 55</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">45, 60</td><td align="center" rowspan="1" colspan="1">0.160<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Number of bypasses</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3, 3</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">3, 4</td><td align="center" rowspan="1" colspan="1">0.485<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Perioperative bleeding (mL)</td><td align="center" rowspan="1" colspan="1">750</td><td align="center" rowspan="1" colspan="1">500, 950</td><td align="center" rowspan="1" colspan="1">725</td><td align="center" rowspan="1" colspan="1">450, 1000</td><td align="center" rowspan="1" colspan="1">0.973<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Bleeding (24h) (mL)</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">200, 400</td><td align="center" rowspan="1" colspan="1">300</td><td align="center" rowspan="1" colspan="1">200, 500</td><td align="center" rowspan="1" colspan="1">0.896<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Total bleeding (mL)</td><td align="center" rowspan="1" colspan="1">1800</td><td align="center" rowspan="1" colspan="1">1300, 2300</td><td align="center" rowspan="1" colspan="1">1775</td><td align="center" rowspan="1" colspan="1">1200, 2300</td><td align="center" rowspan="1" colspan="1">0.999<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Erythrocyte (unit)</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0, 2</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0, 1</td><td align="center" rowspan="1" colspan="1">0.136<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">FFP (unit)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0, 2</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">0, 2</td><td align="center" rowspan="1" colspan="1">0.599<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Intensive care unit stay (day)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1, 4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1, 2</td><td align="center" rowspan="1" colspan="1">0.020<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Drain removal time (day)</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2, 3</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">2, 3</td><td align="center" rowspan="1" colspan="1">0.994<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Clinical admittance (day)</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6, 8</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">6, 7</td><td align="center" rowspan="1" colspan="1">0.370<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Discharge period (day)</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">7, 14</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">7, 8</td><td align="center" rowspan="1" colspan="1">0.051<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">Cross-clamping time (minute)</td><td align="center" rowspan="1" colspan="1">70</td><td align="center" rowspan="1" colspan="1">51, 88</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">40, 67</td><td align="center" rowspan="1" colspan="1">0.040<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr><tr><td align="left" colspan="2" rowspan="1">CPB time (minute)</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">94, 113</td><td align="center" rowspan="1" colspan="1">91.5</td><td align="center" rowspan="1" colspan="1">70, 112</td><td align="center" rowspan="1" colspan="1">0.091<sup><xref ref-type="table-fn" rid="TFN9">a</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN9"><label>a</label><p>Mann-Whitney U test;</p></fn><fn id="TFN10"><label>b</label><p>Pearson's chi-square test;</p></fn><fn id="TFN11"><label>d</label><p>Fisher's exact test;</p></fn><fn id="TFN12"><label>&#x02021;</label><p>No measures of association are computed.</p></fn><fn id="TFN13"><p>CPB=cardiopulmonary bypass; EF=ejection fraction; FFP=fresh-frozen
plasma; IQR=interquartile range, reported as first quartile, third
quartile; LIMA=left internal mammary artery; RIMA=right internal mammary
artery</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>It is a fact that antiplatelet agents, particularly thienopyridine derivative
clopidogrel, are used before PCI in most of the ACS patients<sup>[<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The majority of the ACS patients to whom surgical
revascularization is indicated are candidates for elective CABG surgery while the
remaining minority of them need emergency CABG surgery. In a study, 7-12% of
patients with no ST-elevation myocardial infarction (STEMI) and 4% of patients with
STEMI were reported to undergo CABG surgery during admittance to the same
hospital<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. It is also known that some of the ACS patients undergo
emergency CABG surgery within 24 hours after diagnosis. Therefore, the protocol
recommending discontinuation of clopidogrel 5-7 days before CABG surgery couldn't be
applied to these group of patients. In such emergency conditions, considering
antiplatelet treatment responsible for postoperative bleedings has been a
controversial subject for a long time.</p><p>There is not enough data in the literature about whether clopidogrel use must be
discontinued or not in case of emergency CABG surgery in ACS patients. Some studies
have reported that preoperative clopidogrel use was associated with greater
reoperation rates and increase in use of red blood cell and FFP<sup>[<xref rid="r14" ref-type="bibr">14</xref>,<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Although emergency CABG surgery is required,
administration of antiplatelet treatment is an issue that should be evaluated by
cardiologists and surgeons. In conditions of bleeding or cardiac events, the
interval between treatment discontinuation and CABG surgery is important for the
classification of individual risks. This forces cardiologists, anesthesiologists,
and cardiovascular surgeons to develop shared decision-making strategies for optimal
management of risky patients. Postoperative bleeding makes surgeons anxious while
recurrent ischemic events due to discontinuation of antiplatelet agent make
cardiologists anxious. Because of the bleeding risk, delaying CABG surgery may
increase mortality and morbidity in high-risk patients. In such conditions,
complications like excessive perioperative bleeding and excessive use of blood and
blood products may be neglected. On the other hand, delaying the operation is
another option by discontinuing antiplatelet treatment and taking the risk of
recurrent ischemic events. In contrast to guidelines recommendations, it is reported
that about 87% of non-STEMI patients receiving clopidogrel in the daily practice and
requiring CABG are undergoing surgery within 5 days or less after treatment
discontinuation and this increases the need for blood transfusion<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE)
trial performed with 1015 patients who had undergone CABG surgery during the same
hospitalization period, it was reported that preoperative use of clopidogrel reduced
recurrent ischemic events at a rate of 44%, but an increase was observed in the risk
of perioperative and postoperative bleedings in patients receiving clopidogrel and
ASA within 5 days before surgery<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>.</p><p>In a meta-analysis study by Biancari et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, the authors reported that the use of
clopidogrel before CABG surgery was associated with significant increase in
postoperative death, bleeding, reoperation, and need for blood transfusion. Also, in
a study by Firanescu et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>, the authors reported that there was no difference
between discontinuation of clopidogrel 3 or 5 days before surgery regarding
postoperative bleeding and use of blood and blood products, but there was a
significant difference comparing these patients to those who had undergone surgery
without discontinuing clopidogrel regarding postoperative bleeding and blood and
blood products replacement.</p><p>On the contrary, there are studies stating that there is no difference between
patients undergoing surgery while using clopidogrel or not preoperatively. In a
study with 322 patients by Kim et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, the authors reported that there was no association
between use of clopidogrel within 5 days before CABG surgery and bleeding and
reoperation. Also, in a study by Nagashima et al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>, after comparing groups in which
antithrombotic treatment was stopped and not stopped at 5-7 days before CABG, the
authors found similar total volumes of intraoperative bleeding and bleeding at
postoperative 48 hours between them. Similarly, they stated that they did not find
significant difference between drain removal times and lengths of ICU and hospital
stay. In the study by Karabulut et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, the authors did not observe significant difference
between use of blood and blood products, amount of bleeding, tamponade and
reoperation incidences, and lengths of ICU and hospital stay; and they stated that
the rates of postoperative homolog blood and FFP use were similar in their patients.
Leong et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>
observed no significant relationship between receiving clopidogrel and amount of
bleeding in patients who had undergone off-pump CABG surgery. In the study by Erdem
et al.<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>, patients
receiving different doses of clopidogrel and undergoing emergency PCI and emergency
CABG surgery due to ACS were compared regarding effects of postoperative bleeding,
reoperation due to bleeding, and length of ICU and hospital stay on early mortality.
When the patients receiving high-dose and low-dose of clopidogrel treatment were
compared regarding postoperative chest tube drainage, the authors observed no
significant difference. However, they reported a significant difference in patients
receiving high-dose of clopidogrel compared to patients not receiving
clopidogrel<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.</p><p>In our study, when we compared groups receiving or not clopidogrel preoperatively, we
could not find a significant difference between the amount of perioperative and
postoperative bleeding, rates of reoperation, and tamponade
(<italic>P</italic>&#x0003e;0.05; <xref rid="t2" ref-type="table">Table 2</xref>). We
also found similar drain removal times and lengths of ICU and hospital stays
(<italic>P</italic>&#x0003e;0.05). In patients receiving clopidogrel preoperatively,
while the difference between amounts of erythrocyte and FFP transfusions was not
significant, amounts of fresh blood and platelet transfusions were observed to be
higher (<italic>P</italic>=0.01, <italic>P</italic>=0.02; <xref rid="t2" ref-type="table">Table 2</xref>). Namely, we observed that receiving clopidogrel led to
an increase in the amount of fresh whole blood and platelet transfusions, but it did
not have a significant effect on bleeding and postoperative complications.</p><p>Another issue related to clopidogrel is the resistance. It is estimated that 10-15%
and 29% of the normal population has resistance to ASA and clopidogrel,
respectively. There are also reports indicating that the resistance to aspirin and
clopidogrel is approximately 9%<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. Many factors play a role in resistance to
clopidogrel, and clopidogrel bioavailability shows variability between
individuals<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup>. Inappropriate dose and drug-drug interactions are
other factors affecting the conversion of clopidogrel to its active metabolite.
Another important determinant is the genetic polymorphism of the P2Y12 receptor.
Certain receptor alleles, ineffective binding to ADP receptor antagonists, and
polymorphisms of cytochrome p450 system may also cause resistance. Also, modified
risk factors like smoking and stress may play a role<sup>[<xref rid="r27" ref-type="bibr">27</xref>]</sup>. Resistance to clopidogrel
may cause many disadvantageous conditions in terms of cardiology, such as
thromboembolic events. Many studies showed that the determination of platelet
reactivity levels played a role in the prediction of bleeding risk and, indirectly,
in the surgery timing<sup>[<xref rid="r28" ref-type="bibr">28</xref>,<xref rid="r29" ref-type="bibr">29</xref>]</sup>. There are studies finding
that platelet function tests in the early period are recommendable for guiding
treatment discontinuation. It is said that this condition may permit waiting time to
be 50% shorter than recommended by guidelines<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup>.</p><p>In our cases, as indicated earlier, no significant difference was determined between
patients receiving clopidogrel and those not, regarding amounts of total bleeding,
erythrocyte suspension transfusion, and FFP replacement. We observed that resistance
to clopidogrel among patients receiving clopidogrel did not affect the amount of
total bleeding, erythrocyte suspension, FFP replacement, and the length of
hospitalization (<italic>P</italic>=0.999, <italic>P</italic>=0.136, and
<italic>P</italic>=0.599, respectively; <xref rid="t3" ref-type="table">Table
3</xref>). However, lengths of ICU and cross-clamping times of
clopidogrel-resistant patients (<xref ref-type="fig" rid="f1">Figure 1</xref>)
(<italic>P</italic>=0.020, <italic>P</italic>=0.040) were observed to be
statistically significant (<italic>P</italic>&#x0003c;0.05).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Clopidogrel resistance/cross-clamping time relationship.</p></caption><graphic xlink:href="rbccv-33-04-0330-g01"/></fig>
</p><p>During comparison of patients with and without clopidogrel resistance among the ones
receiving clopidogrel, no significant difference was determined between troponin
values, preoperative and postoperative EF values, total bleeding volumes during and
after surgery, amount of erythrocyte suspension (ERT) and FFP transfusions, and
length of hospitalization (<xref rid="t3" ref-type="table">Table 3</xref>;
<italic>P</italic>&#x0003e;0.05).</p><sec><title>Limitations</title><p>The limitations of our study are a small number of patients and the fact that it
is a single center study. Unfortunately, since there is a great variability in
individual response among patients treated with antiplatelet agents, especially
with clopidogrel, it is hard to predetermine clearly which patient is exposed to
the risk of excessive bleeding and transfusion. It can be difficult to predict
only by looking for clopidogrel resistance preoperatively. Keeping in mind that
genetic polymorphism of the P2Y12 receptor is also an important factor, it can
be useful to perform a meta-analysis of a multicenter genetic study, increasing
the samples.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>It was observed that the presence or absence of resistance to clopidogrel did not
cause a difference in the postoperative period of patients regarding erythrocyte
suspension transfusion, FFP replacement, and bleeding-related complications. Also,
considering the current costs, we think that resistance studies in patients
receiving clopidogrel before cardiac surgery cannot be a routine efficient test to
predict bleeding and bleeding-related complications in patients undergoing or who
might undergo emergency CABG surgery. We think that it could be useful to hold
preparations of fresh blood, erythrocyte suspension, FFP, and platelet suspension on
hand as they could be needed in addition to surgical diligence regarding bleeding
and bleeding-related complications in patients undergoing emergency CABG surgery
while receiving clopidogrel.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">MK</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ZA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">UV</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AYB</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AAA</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SY</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final manuscript approval</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Department of Cardiovascular Surgery, Dr.
Siyami Ersek Training and Research Hospital, University of Health Sciences,
&#x00130;stanbul, Turkey.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coukell</surname><given-names>AJ</given-names></name><name><surname>Markham</surname><given-names>A</given-names></name></person-group><article-title>Clopidogrel</article-title><source>Drugs</source><year>1997</year><volume>54</volume><issue>5</issue><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">9360060</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name><name><surname>Casey Jr</surname><given-names>DE</given-names></name><name><surname>Ettinger</surname><given-names>SM</given-names></name><etal/></person-group><article-title>2011 ACCF/AHA Focused update of the guidelines for the management
of patients with unstable angina/ non-ST-elevation myocardial infarction
(Updating the 2007 Guideline): a report of the American College of
Cardiology Foundation/American Heart Association Task Force on Practice
Guidelines</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>18</issue><fpage>2022</fpage><lpage>2060</lpage><pub-id pub-id-type="pmid">21444889</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burke</surname><given-names>MA</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name><name><surname>Fintel</surname><given-names>DJ</given-names></name></person-group><article-title>Early clopidogrel use in non-ST elevation acute coronary syndrome
and subsequent coronary artery bypass grafting</article-title><source>Am Heart J</source><year>2011</year><volume>161</volume><issue>5</issue><fpage>832</fpage><lpage>841</lpage><pub-id pub-id-type="pmid">21570511</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kremke</surname><given-names>M</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Bak</surname><given-names>M</given-names></name><name><surname>Kristensen</surname><given-names>KL</given-names></name><name><surname>Hindsholm</surname><given-names>K</given-names></name><name><surname>Andreasen</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Antiplatelet therapy at the time of coronary artery bypass
grafting: a multicentre cohort study</article-title><source>Eur J Cardiothorac Surg</source><year>2013</year><volume>44</volume><issue>2</issue><fpage>e133</fpage><lpage>e140</lpage><pub-id pub-id-type="pmid">23660554</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>JS</given-names></name><name><surname>Frye</surname><given-names>CB</given-names></name><name><surname>Harshaw</surname><given-names>Q</given-names></name><name><surname>Edwards</surname><given-names>FH</given-names></name><name><surname>Steinhubl</surname><given-names>SR</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name></person-group><article-title>Impact of clopidogrel in patients with acute coronary syndromes
requiring coronary artery bypass surgery: a multicenter
analysis</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><issue>21</issue><fpage>1693</fpage><lpage>1701</lpage><pub-id pub-id-type="pmid">19007688</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatine</surname><given-names>MS</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>L&#x000f3;pez-Send&#x000f3;n</surname><given-names>JL</given-names></name><name><surname>Montalescot</surname><given-names>G</given-names></name><name><surname>Theroux</surname><given-names>P</given-names></name><etal/><collab>Clopidogrel as adjunctive reperfusion therapy (CLARITY)-Thrombolysis
in Myocardial Infarction (TIMI) 28 Investigators</collab></person-group><article-title>Effect of clopidogrel pretreatment before percutaneous coronary
intervention in patients with ST-elevation myocardial infarction treated
with fibrinolytics: the PCI-CLARITY study</article-title><source>JAMA</source><year>2005</year><volume>294</volume><issue>10</issue><fpage>1224</fpage><lpage>1232</lpage><pub-id pub-id-type="pmid">16143698</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sueta</surname><given-names>D</given-names></name><name><surname>Hokimoto</surname><given-names>S</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name></person-group><article-title>Could perioperative bleeding complications be predicted using a
platelet aggregation test?</article-title><source>Thromb Res</source><year>2015</year><volume>136</volume><issue>3</issue><fpage>491</fpage><lpage>492</lpage><pub-id pub-id-type="pmid">26139088</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Bracey</surname><given-names>AW</given-names></name><name><surname>Radovancevic</surname><given-names>R</given-names></name><name><surname>Cooper Jr</surname><given-names>JR</given-names></name><name><surname>Collard</surname><given-names>CD</given-names></name><name><surname>Vaughn</surname><given-names>WK</given-names></name><etal/></person-group><article-title>Clopidogrel and bleeding in patients undergoing elective coronary
artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><year>2004</year><volume>128</volume><issue>3</issue><fpage>425</fpage><lpage>431</lpage><pub-id pub-id-type="pmid">15354103</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gurbel</surname><given-names>PA</given-names></name><name><surname>Bliden</surname><given-names>KP</given-names></name><name><surname>Hiatt</surname><given-names>BL</given-names></name><name><surname>O'Connor</surname><given-names>CM</given-names></name></person-group><article-title>Clopidogrel for coronary stenting: response variability, drug
resistance, and the effect of pretreatment platelet
reactivity</article-title><source>Circulation</source><year>2003</year><volume>107</volume><issue>23</issue><fpage>2908</fpage><lpage>2913</lpage><pub-id pub-id-type="pmid">12796140</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>SV</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Gibson</surname><given-names>CM</given-names></name><name><surname>Caixeta</surname><given-names>A</given-names></name><name><surname>Eikelboom</surname><given-names>J</given-names></name><etal/></person-group><article-title>Standardized bleeding definitions for cardiovascular clinical
trials: a consensus report from the Bleeding Academic Research
Consortium</article-title><source>Circulation</source><year>2011</year><volume>123</volume><issue>23</issue><fpage>2736</fpage><lpage>2747</lpage><pub-id pub-id-type="pmid">21670242</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amsterdam</surname><given-names>EA</given-names></name><name><surname>Wenger</surname><given-names>NK</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Casey Jr</surname><given-names>DE</given-names></name><name><surname>Ganiats</surname><given-names>TG</given-names></name><name><surname>Holmes Jr</surname><given-names>DR</given-names></name><etal/><collab>ACC/AHA Task Force Members</collab></person-group><article-title>2014 AHA/ACC guideline for the management of patients with
non-ST-elevation acute coronary syndromes: a report of the American College
of Cardiology/American Heart Association Task Force on Practice
Guidelines</article-title><source>Circulation</source><year>2014</year><volume>130</volume><issue>25</issue><fpage>e344</fpage><lpage>e426</lpage><pub-id pub-id-type="pmid">25249585</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>RV</given-names></name><name><surname>Goodman</surname><given-names>SG</given-names></name><name><surname>Yan</surname><given-names>RT</given-names></name><name><surname>Spencer</surname><given-names>FA</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>DeYoung</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Temporal trends and patterns of early clopidogrel use across the
spectrum of acute coronary syndromes</article-title><source>Am Heart J</source><year>2009</year><volume>157</volume><issue>4</issue><fpage>642</fpage><lpage>650</lpage><pub-id pub-id-type="pmid">19332190</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Anderson Jr</surname><given-names>FA</given-names></name><name><surname>Dabbous</surname><given-names>OH</given-names></name><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>L&#x000f3;pez-Send&#x000f3;n</surname><given-names>J</given-names></name><name><surname>Van de Werf</surname><given-names>F</given-names></name><etal/><collab>GRACE Investigators</collab></person-group><article-title>Intervention in acute coronary syndromes: do patients undergo
intervention on the basis of their risk characteristics? The Global Registry
of Acute Coronary Events (GRACE)</article-title><source>Heart</source><year>2007</year><volume>93</volume><issue>2</issue><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">16757543</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yende</surname><given-names>S</given-names></name><name><surname>Wunderink</surname><given-names>RG</given-names></name></person-group><article-title>Effect of clopidogrel on bleeding after coronary artery bypass
surgery</article-title><source>Crit Care Med</source><year>2002</year><volume>29</volume><issue>12</issue><fpage>2271</fpage><lpage>2275</lpage></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Chrolavicius</surname><given-names>S</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>KK</given-names></name><collab>Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial
Investigators</collab></person-group><article-title>Effects of clopidogrel in addition to aspirin in patients with
acute coronary syndromes without ST-segment elevation</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><issue>7</issue><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">11519503</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>RH</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Mulgund</surname><given-names>J</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Gibler</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Acute clopidogrel use and outcomes in patients with
non-ST-segment elevation acute coronary syndromes undergoing coronary artery
bypass surgery</article-title><source>J Am Coll Cardiol</source><year>2006</year><volume>48</volume><issue>2</issue><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">16843176</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Peters</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Lakkis</surname><given-names>N</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Clopidogrel in unstable angina to prevent recurrent ischemic
events trial. Benefits and risks of the combination of clopidogrel and
aspirin in patients undergoing surgical revascularization for
non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina
to prevent Recurrent ischemic Events (CURE) Trial</article-title><source>Circulation</source><year>2004</year><volume>110</volume><issue>10</issue><fpage>1202</fpage><lpage>1208</lpage><pub-id pub-id-type="pmid">15313956</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biancari</surname><given-names>F</given-names></name><name><surname>Airaksinen</surname><given-names>KE</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Benefits and risks of using clopidogrel before coronary artery
bypass surgery: systematic review and meta-analysis of randomized trials and
observational studies</article-title><source>J Thorac Cardiovasc Surg</source><year>2012</year><volume>143</volume><issue>3</issue><fpage>665</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">21703636</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firanescu</surname><given-names>CE</given-names></name><name><surname>Martens</surname><given-names>EJ</given-names></name><name><surname>Sch&#x000f6;nberger</surname><given-names>JP</given-names></name><name><surname>Soliman Hamad</surname><given-names>MA</given-names></name><name><surname>van Straten</surname><given-names>AH</given-names></name></person-group><article-title>Postoperative blood loss in patients undergoing coronary artery
bypass surgery after preoperative treatment with clopidogrel. A prospective
randomised controlled study</article-title><source>Eur J Cardiothorac Surg</source><year>2009</year><volume>36</volume><issue>5</issue><fpage>856</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">19616440</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Newby</surname><given-names>LK</given-names></name><name><surname>Clare</surname><given-names>RM</given-names></name><name><surname>Shaw</surname><given-names>LK</given-names></name><name><surname>Lodge</surname><given-names>AJ</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Clopidogrel use and bleeding after coronary artery bypass graft
surgery</article-title><source>Am Heart J</source><year>2008</year><volume>156</volume><issue>5</issue><fpage>886</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">19061702</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagashima</surname><given-names>Z</given-names></name><name><surname>Tsukahara</surname><given-names>K</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Hibi</surname><given-names>K</given-names></name><name><surname>Karube</surname><given-names>N</given-names></name><name><surname>Ebina</surname><given-names>T</given-names></name><etal/></person-group><article-title>Impact of preoperative dual antiplatelet therapy on bleeding
complications in patients with acute coronary syndromes who undergo urgent
coronary artery bypass grafting</article-title><source>J Cardiol</source><year>2017</year><volume>69</volume><issue>1</issue><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="pmid">26987791</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karabulut</surname><given-names>H</given-names></name><name><surname>Toraman</surname><given-names>F</given-names></name><name><surname>Evrenkaya</surname><given-names>S</given-names></name><name><surname>Goksel</surname><given-names>O</given-names></name><name><surname>Tarcan</surname><given-names>S</given-names></name><name><surname>Alhan</surname><given-names>C</given-names></name></person-group><article-title>Clopidogrel does not increase bleeding and allogenic blood
transfusion in coronary artery surgery</article-title><source>Eur J Cardiothorac Surg</source><year>2004</year><volume>25</volume><issue>3</issue><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">15019671</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>JY</given-names></name><name><surname>Baker</surname><given-names>RA</given-names></name><name><surname>Shah</surname><given-names>PJ</given-names></name><name><surname>Cherian</surname><given-names>VK</given-names></name><name><surname>Knight</surname><given-names>JL</given-names></name></person-group><article-title>Clopidogrel and bleeding after coronary artery bypass graft
surgery</article-title><source>Ann Thorac Surg</source><year>2005</year><volume>80</volume><issue>3</issue><fpage>928</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">16122457</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erdem</surname><given-names>K</given-names></name><name><surname>Mercan</surname><given-names>H</given-names></name><name><surname>Ozdemir</surname><given-names>L</given-names></name></person-group><article-title>The effects of clopidogrel loading doses on postoperative
bleeding in patients with acute coronary syndrome requiring emergent
coronary bypass surgery</article-title><source>Turkish J Thorac Cardiovasc Surg</source><year>2012</year><volume>20</volume><issue>4</issue><fpage>755</fpage><lpage>760</lpage></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nappi</surname><given-names>J</given-names></name></person-group><article-title>Benefits and limitations of current antiplatelet
therapies</article-title><source>Am J Health Syst Pharm</source><year>2008</year><volume>65</volume><issue>13</issue><supplement>Suppl 5</supplement><fpage>S5</fpage><lpage>10</lpage></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>MJ</given-names></name><name><surname>Walder</surname><given-names>JS</given-names></name><name><surname>Baker</surname><given-names>BA</given-names></name><name><surname>Heiselman</surname><given-names>DE</given-names></name><name><surname>Jakubowski</surname><given-names>JA</given-names></name><name><surname>Logan</surname><given-names>DK</given-names></name><etal/></person-group><article-title>Recovery of platelet function after discontinuation of prasugrel
or clopidogrel maintenance dosing in aspirin-treated patients with stable
coronary disease: the recovery trial</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><issue>25</issue><fpage>2338</fpage><lpage>2343</lpage><pub-id pub-id-type="pmid">22698488</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>TA</given-names></name><name><surname>Diodati</surname><given-names>JG</given-names></name><name><surname>Pharand</surname><given-names>C</given-names></name></person-group><article-title>Resistance to clopidogrel: a review of the
evidence</article-title><source>J Am Coll Cardiol</source><year>2005</year><volume>45</volume><issue>8</issue><fpage>1157</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">15837243</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poston</surname><given-names>R</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Manchio</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Gammie</surname><given-names>J</given-names></name><etal/></person-group><article-title>Platelet function tests predict bleeding and thrombotic events
after off-pump coronary bypass grafting</article-title><source>Eur J Cardiothorac Surg</source><year>2005</year><volume>27</volume><issue>4</issue><fpage>584</fpage><lpage>591</lpage><pub-id pub-id-type="pmid">15784355</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ranucci</surname><given-names>M</given-names></name><name><surname>Baryshnikova</surname><given-names>E</given-names></name><name><surname>Soro</surname><given-names>G</given-names></name><name><surname>Ballotta</surname><given-names>A</given-names></name><name><surname>De Benedetti</surname><given-names>D</given-names></name><name><surname>Conti</surname><given-names>D</given-names></name><collab>Surgical and Clinical Outcome Research (SCORE) Group</collab></person-group><article-title>Multiple electrode whole-blood aggregometry and bleeding in
cardiac surgery patients receiving thienopyridines</article-title><source>Ann Thorac Surg</source><year>2011</year><volume>91</volume><issue>1</issue><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">21172499</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Yoo</surname><given-names>KJ</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Shim</surname><given-names>JK</given-names></name></person-group><article-title>Clopidogrel responsiveness regardless of the discontinuation date
predicts increased blood loss and transfusion requirement after off-pump
coronary artery bypass graft surgery</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><issue>24</issue><fpage>1994</fpage><lpage>2002</lpage><pub-id pub-id-type="pmid">21126640</pub-id></element-citation></ref></ref-list></back></article>